Tislelizumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Tislelizumab
ATC codes	L01FF09
Medicine type	Biological agent
EML status history	Application rejected in 2021 (TRS 1035) for Hodgkin lymphoma Application rejected in 2021 (TRS 1035) for Malignant neoplasms of urinary tract Application rejected in 2023 (TRS 1049) for Other specified malignant neoplasms of bronchus or lung Application rejected in 2025 (TRS 1064) for Squamous cell carcinoma of oesophagus
Wikipedia	Tislelizumab
DrugBank	Tislelizumab

Recommendations

Section Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

Hodgkin lymphoma

Malignant neoplasms of urinary tract

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oesophagus